Life Sciences Tools and Services
Company Overview of CyDex Pharmaceuticals, Inc.
CyDex Pharmaceuticals, Inc. develops a formulation technology that enables product development by improving solubility, stability, bioavailability, and dosing of active pharmaceutical ingredients (APIs). It offers Captisol technology, which is a polyanionic beta-cyclodextrin derivative with a sodium sulfonate salt separated from the lipophilic cavity by a butyl ether spacer group or sulfobutylether that allows formulation of water-insoluble APIs in various dosage forms, including oral, injectables, ophthalmic, nasal, topical, and inhalation products. The company also provides pharmaceutical product development services, commercial licenses and supply agreements, and limited clinical use agre...
10513 West 84th Terrace
Lenexa, KS 66214
Founded in 1990
Key Executives for CyDex Pharmaceuticals, Inc.
Senior Director of Business Development and Investor Relations
Vice President of Business Development & Marketing
Director of Corporate Development
Compensation as of Fiscal Year 2015.
CyDex Pharmaceuticals, Inc. Key Developments
Marinus Pharmaceuticals Seals Deal with CyDex Pharmaceuticals, Inc. for Clinical Use of Captisol
Aug 12 14
Marinus Pharmaceuticals signed an agreement with CyDex Pharmaceuticals for the clinical use of Captisol. Captisol is a uniquely modified cyclodextrin, whose chemical structure was designed to improve solubility, stability, bioavailability and dosing of active pharmaceutical ingredients. MRNS said it plans to use Captisol to evaluate ways to optimize its intravenous dose form of ganaxolone.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries